Skip to main content
. 2015 Sep 24;4(10):e002469. doi: 10.1161/JAHA.115.002469

Table 3.

Discharge/Follow‐Up Characteristics

Na Nonskiers N=4881 Skiers N=1083 P Valueb
Severity of stroke
Mobility 5231 <0.001
Deceased 351 (8.3) 73 (7.5)
No assistance 3271 (76.9) 819 (83.8)
With assistance indoors 310 (7.3) 44 (4.5)
With assistancec 322 (7.6) 41 (4.2)
Need assistance for toilet visits 4812 385 (9.9) 51 (5.6) <0.001
Dressing with assistance 4809 470 (12.0) 67 (7.4) <0.001
Dependent 4066 0.001
Partially 1132 (34.3) 229 (29.9)
Totally 292 (8.9) 49 (6.4)
Speaking problems 2356 512 (27.1) 111 (23.8) 0.15
Depressive mode 4028 <0.001
Almost never 1438 (44.1) 418 (54.4)
Sometimes 1477 (43.3) 306 (39.8)
General health 3983 <0.001
Poor 67 (2.1) 9 (1.2)
Bad 427 (13.2) 48 (6.3)
Good 2181 (67.6) 499 (65.8)
Very good 550 (17.1) 202 (26.6)
Smoking 3474 398 (14.2) 24 (3.5) <0.001
Discharge/follow‐up treatments
Hypertension treatment 3394 1989 (72.8) 383 (57.9) <0.001
Warfarin 5003 411 (10.0) 132 (14.5) <0.001
Thrombolysis 5137 192 (4.6) 60 (6.4) 0.017
Calcium antagonists 4127 467 (23.2) 130 (16.8) <0.001
ACE‐inhibitors 2767 931 (41.3) 182 (35.4) <0.014
Angiotensin II‐blockers 2766 263 (11.7) 42 (8.2) <0.022
Diuretics 4127 740 (22.1) 118 (15.2) <0.001
Statins 4127 1958 (58.4) 438 (56.5) 0.33
Aspirin 5015 2611 (63.6) 554 (60.9) 0.13
Clopidogrel 4128 213 (6.4) 48 (6.2) 0.87
Aspirin+clopidogrel 4131 136 (4.1) 36 (4.6) 0.46
Dipyridamole 4138 491 (14.6) 103 (13.3) 0.33

Numbers represent frequencies with percentages in parentheses. Note that the denominator is different between variables due to partial missing of data. ACE indicates angiotensin‐converting enzyme; Nonskiers, population‐based controls with the same age, sex, and same county of residence; Skiers, the participants in the Vasaloppet.

a

Number of nonmissing observations.

b

Pearson χ2 test.

c

From 2001.